Table 4.
Logistic regression analysis of adverse reactions in patients with colorectal cancer
| Adverse events | Gene type | B | SE | Z | P | OR (95%CI) |
| *After adjusting the number of treatment lines, treatment plan, smoking, gender, tumor type and hyperbilirubinemia. | ||||||
| *Vomit | UGT1A1*6 | 1.250 | 0.590 | 2.118 | 0.034 | 3.49 (1.10-11.10) |
| UGT1A1*28 | 1.029 | 0.680 | 1.513 | 0.130 | 2.80 (0.74-10.62) | |
| *Vomit grade | UGT1A1*6 | 2.236 | 0.786 | 2.843 | 0.004 | 9.36 (2.00-43.70) |
| UGT1A1*28 | 1.481 | 0.761 | 1.945 | 0.052 | 4.40 (0.99-19.55) | |
| *Diarrhea grade | UGT1A1*6 | 2.166 | 0.767 | 2.824 | 0.005 | 8.72 (1.94-39.22) |
| UGT1A1*28 | -0.899 | 0.963 | -0.933 | 0.351 | 0.41 (0.06-2.69) | |
| *Neutropenia grade | UGT1A1*6 | 1.484 | 0.595 | 2.492 | 0.013 | 4.41 (1.37-14.16) |
| UGT1A1*28 | 0.825 | 0.668 | 1.235 | 0.217 | 2.28 (0.62-8.44) | |